Background: Whereas most adequately treated children with congenital hypothyroidism (CH) do well neurodevelopmentally, when both the maternal and fetal thyroid glands are compromised, significant cognitive delay can occur despite early and aggressive postnatal therapy. Maternal thyrotropin-stimulating hormone receptor (TSHR)-blocking antibodies (Abs) can be transmitted to the fetus and cause combined maternal-fetal hypothyroidism. Current guidelines recommend their measurement only if mothers have known autoimmune thyroid disease, there is a history of a previously affected sibling, or when transient CH is suspected. Results: We report 3 infants in whom the diagnosis of maternal hypothyroidism was not known and was identified only after CH was diagnosed in their babies. One of these infants had developmental delay despite rapid normalization of thyroid function postnatally. All 3 mothers had potent TSHR Abs in serum, but thyroid peroxidase Abs and thyroglobulin Abs were detectable in only 2 of them. Conclusions: TSHR-blocking Ab-induced CH should be suspected in any baby with CH irrespective of the known family history, especially if the hypothyroidism is severe and a eutopic thyroid gland is demonstrated on imaging. Measurement of TSHR Abs is necessary to establish the diagnosis; the presence of other thyroid Abs is insufficiently sensitive and may miss some cases.

1.
Rose SR, Brown RS, Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK: Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006;117:2290-2303.
2.
Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, Van Vliet G, Polak M, Butler G: European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014;99:363-384.
3.
Dimitropoulos A, Molinari L, Etter K, Lang-Muritano M, Jenni OG, Largo RH, Latal B: Children with congenital hypothyroidism: long-term intellectual outcome after early high-dose treatment. Pediatric Res 2009;65:242-248.
4.
Fisher DA: The importance of early management in optimizing IQ in infants with congenital hypothyroidism. J Pediatr 2000;136:273-274.
5.
Dubuis JM, Glorieux J, Richer F, Deal CL, Dussault JH, Van Vliet G: Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. J Clin Endocrinol Metab 1996;81:222-227.
6.
Smallridge RC, Ladenson PW: Hypothyroidism in pregnancy: consequences to neonatal health. J Clin Endocrinol Metab 2001;86:2349-2353.
7.
Brown RS, Bellisario RL, Botero D, Fournier L, Abrams CA, Cowger ML, David R, Fort P, Richman RA: Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies. J Clin Endocrinol Metab 1996;81:1147-1151.
8.
Matsuura N, Konishi J: Transient hypothyroidism in infants born to mothers with chronic thyroiditis - a nationwide study of twenty-three cases. The Transient Hypothyroidism Study Group. Endocrinol Jpn 1990;37:369-379.
9.
Southgate K, Creagh F, Teece M, Kingswood C, Rees Smith B: A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol (Oxf) 1984;20:539-548.
10.
Cao XY, Jiang XM, Dou ZH, Rakeman MA, Zhang ML, O'Donnell K, Ma T, Amette K, DeLong N, DeLong GR: Timing of vulnerability of the brain to iodine deficiency in endemic cretinism. N Engl J Med 1994;331:1739-1744.
11.
de Zegher F, Pernasetti F, Vanhole C, Devlieger H, Van den Berghe G, Martial JA: The prenatal role of thyroid hormone evidenced by fetomaternal PIT-1 deficiency. J Clin Endocrinol Metab 1995;80:3127-3130.
12.
Vulsma T, Gons MH, de Vijlder JJ: Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989;321:13-16.
13.
Connors MH, Styne DM: Transient neonatal ‘athyreosis' resulting from thyrotropin-binding inhibitory immunoglobulins. Pediatrics 1986;78:287-290.
14.
Brown RS, Keating P, Mitchell E: Maternal thyroid-blocking immunoglobulins in congenital hypothyroidism. J Clin Endocrinol Metab 1990;70:1341-1346.
15.
Zophel K, Rogggenbuck D, Schott M: Clinical review about TRAb assay's history. Autoimmun Rev 2010;9:695-700.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.